Nuclear Imaging Devices Market Size & Growth Forecast 2027–2036, By Segments (End-use, End User, Product Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Nuclear Imaging Devices Market size was valued at USD 3.41 Billion in 2026 and is anticipated to grow at 5.29% CAGR from 2027 to 2036, surpassing USD 5.71 Billion by 2036. The industry revenue for 2027 is calculated at USD 3.56 Billion.

• Base Year Value (2026): USD 3.41 Billion
• CAGR (2027-2036): 5.29%
• Forecast Year Value (2036): USD 5.71 Billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Nuclear Imaging Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America led in 2025 due to advanced healthcare infrastructure, established nuclear medicine capabilities, and strong demand for sophisticated disease detection and monitoring.
  • Asia Pacific is projected to grow fastest as healthcare infrastructure improves, diagnostic awareness rises, and investment expands in modern facilities and specialized imaging services.

• Segment Momentum:

  • Oncology accounted for 51.94% share in 2025, driven by nuclear imaging’s role in cancer detection, treatment planning, and therapy monitoring.
  • PET is the fastest-growing product segment due to its advanced metabolic imaging capabilities, supporting precise diagnosis, treatment monitoring, and precision medicine applications.

• Market Expansion Drivers:

  • Growing prevalence of chronic diseases increasing demand for advanced diagnostic imaging
  • Technological advancements in PET and SPECT imaging improving diagnostic accuracy
  • Favorable government funding supporting modernization of nuclear imaging infrastructure

• Leading Market Participants:

  Leading players in the nuclear imaging devices market include Koninklijke Philips N.V. (Netherlands), GE HealthCare Technologies Inc. (United States), Siemens Healthineers AG (Germany), Canon Medical Systems Corporation (Japan), Digirad Corporation (United States), Neusoft Medical Systems Co., Ltd. (China), Spectrum Dynamics Medical (Israel), Mediso Ltd. (Hungary), Capintec, Inc. (United States), Positron Corporation (United States)

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 3.41 Billion
  • 2027 Estimated Market Size: USD 3.56 Billion
  • Projected Market Size: USD 5.71 Billion by 2036
  • Growth Forecasts: 5.29% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Oncology (End-use) | Hospitals (End User) | Single Photon Emission Computed Tomography (SPECT) (Product Type)
  • Emerging Opportunity Segment: Neurology (End-use) | Diagnostic Imaging Centers (End User) | Positron Emission Tomography (PET) (Product Type)

Market Growth Drivers and Industry Trends

Growing prevalence of chronic diseases increasing demand for advanced diagnostic imaging

The rising incidence of chronic conditions such as cardiovascular disorders, cancer, and neurological diseases is creating a greater need for early and accurate diagnosis, which will drive the nuclear imaging devices market growth. Nuclear imaging technologies provide functional insights that complement conventional anatomical imaging, enabling clinicians to identify disease progression, evaluate organ performance, and support personalized treatment planning. Healthcare providers are increasingly integrating these imaging modalities into routine diagnostic pathways to improve clinical decision-making and monitor therapeutic outcomes. The growing emphasis on timely disease detection has also encouraged hospitals and diagnostic centers to expand their advanced imaging capabilities for complex patient management.

Technological advancements in PET and SPECT imaging improving diagnostic accuracy

Continuous innovation in imaging hardware and software is strengthening the clinical value of PET and SPECT systems, and the nuclear imaging devices market is benefiting from the improved precision and efficiency these advancements deliver. Developments such as higher-resolution detectors, enhanced image reconstruction algorithms, hybrid imaging platforms, and faster acquisition techniques enable healthcare professionals to identify abnormalities with greater confidence while improving patient comfort during examinations. Modern systems also support more efficient workflows by reducing scan times and optimizing image quality across a wide range of clinical applications. These technological improvements are encouraging healthcare facilities to upgrade existing equipment and adopt next-generation imaging solutions that support accurate diagnosis across multiple medical specialties.

Favorable government funding supporting modernization of nuclear imaging infrastructure

Public sector investments aimed at strengthening healthcare infrastructure will propel the nuclear imaging devices market growth by facilitating the modernization of diagnostic imaging facilities. Governments are allocating financial support for the replacement of aging imaging equipment, expansion of specialized diagnostic centers, and improvement of access to advanced medical technologies in both urban and underserved regions. Funding initiatives also encourage the adoption of modern imaging systems that comply with evolving quality and safety standards while supporting improved healthcare delivery. In addition, investments in medical research institutions and public healthcare networks contribute to broader utilization of nuclear imaging technologies for disease diagnosis, treatment planning, and clinical research.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Growing prevalence of chronic diseases increasing demand for advanced diagnostic imaging	2.1%	High	North America, Europe	High	Near Term
Technological advancements in PET and SPECT imaging improving diagnostic accuracy	2%	High	North America, Asia Pacific	High	Mid Term
Favorable government funding supporting modernization of nuclear imaging infrastructure	1.9%	High	North America, Europe	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

In the nuclear imaging devices market, North America maintained the leading position in 2026, supported by advanced healthcare infrastructure, widespread availability of diagnostic imaging technologies, and strong demand for sophisticated disease detection and monitoring solutions. The region benefits from established nuclear medicine capabilities and growing utilization of imaging techniques for oncology, cardiology, and neurological applications. Continued technological advancement and emphasis on early diagnosis are further supporting the integration of nuclear imaging devices into clinical care.

Asia Pacific is anticipated to register the fastest growth, encouraged by improving healthcare infrastructure, rising awareness of advanced diagnostic procedures, and increasing demand for medical imaging services. Expanding access to specialized healthcare and greater investment in modern diagnostic facilities are creating opportunities for nuclear imaging adoption. In addition, the growing burden of chronic diseases and the increasing focus on earlier and more precise diagnosis are supporting the development of nuclear medicine capabilities across the region.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

End-use Segment Analysis: Oncology (Largest Segment) vs Neurology (Fastest-Growing Segment)

The oncology segment dominated the nuclear imaging devices market with a 51.94% share in 2026. Nuclear imaging technologies are extensively utilized in cancer detection, staging, treatment planning, and therapy monitoring due to their ability to provide detailed functional information about tumors. The growing emphasis on early diagnosis and precision medicine has strengthened the role of nuclear imaging in oncology workflows. Additionally, the increasing use of advanced imaging techniques for evaluating treatment response continues to support the segment’s leading position.

Neurology is the fastest-growing end-use segment, driven by rising interest in the diagnosis and management of neurological disorders. Nuclear imaging plays an important role in assessing brain function, identifying neurodegenerative conditions, and supporting research into complex neurological diseases. Growing awareness of brain health, combined with advances in imaging technologies that enable earlier and more accurate diagnosis, is accelerating adoption within neurological applications.

End User Segment Analysis: Hospitals (Largest Segment) vs Diagnostic Imaging Centers (Fastest-Growing Segment)

Hospitals held the largest share of the market in 2026. Their leadership is supported by comprehensive healthcare infrastructure, access to specialized medical professionals, and the availability of advanced imaging equipment required for nuclear medicine procedures. Hospitals often manage a broad range of complex cases requiring integrated diagnostic and treatment services, making them the primary setting for nuclear imaging utilization. Continued investments in diagnostic capabilities further reinforce their dominant market position.

Diagnostic imaging centers are emerging as the fastest-growing end-user segment due to their ability to provide specialized imaging services with greater accessibility and operational efficiency. These facilities often offer focused expertise, shorter waiting times, and dedicated diagnostic workflows, making them increasingly attractive to both patients and referring physicians. Rising demand for outpatient diagnostic services is contributing significantly to segment growth.

Product Type Segment Analysis: Single Photon Emission Computed Tomography (SPECT) (Largest Segment) vs Positron Emission Tomography (PET) (Fastest-Growing Segment)

Single photon emission computed tomography (SPECT) accounted for the largest share of the nuclear imaging devices market in 2026. The technology is widely utilized across cardiology, oncology, and neurology applications due to its established clinical utility, broad availability, and cost-effective diagnostic capabilities. SPECT systems support functional imaging across a variety of disease areas, making them an integral component of nuclear medicine departments worldwide.

Positron emission tomography (PET) is the fastest-growing product type segment, supported by its superior sensitivity and ability to provide detailed metabolic and molecular information. PET imaging is increasingly adopted for advanced disease characterization, treatment monitoring, and precision medicine applications. Ongoing advancements in radiotracer development and the growing demand for highly accurate diagnostic imaging are further accelerating the expansion of the PET segment.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
End-use	Oncology, Neurology, Cardiology, Others	Oncology	Neurology
End User	Hospitals, Diagnostic Imaging Centers, Others	Hospitals	Diagnostic Imaging Centers
Product Type	Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Planar Scintigraphy, Others	Single Photon Emission Computed Tomography (SPECT)	Positron Emission Tomography (PET)

Competitive Landscape and Market Positioning

Major players in the nuclear imaging devices market:

1. Koninklijke Philips N.V. (Netherlands)
2. GE HealthCare Technologies, Inc. (United States)
3. Siemens Healthineers AG (Germany)
4. Canon Medical Systems Corporation (Japan)
5. Digirad Corporation (United States)
6. Neusoft Medical Systems Co., Ltd. (China)
7. Spectrum Dynamics Medical (Israel)
8. Mediso Ltd. (Hungary)
9. Capintec, Inc. (United States)
10. Positron Corporation (United States)

The Nuclear Imaging Devices Market is evolving around competition for improved diagnostic precision, workflow efficiency, and broader clinical applicability. Device manufacturers are focusing on advancing imaging performance while addressing healthcare providers’ demand for solutions that enhance patient evaluation and streamline operational processes. Differentiation is increasingly tied to the ability to integrate advanced imaging technologies with supportive software capabilities and adaptable clinical workflows. Established participants leverage deep healthcare expertise and service infrastructure, while specialized innovators pursue opportunities through focused solutions designed for emerging diagnostic requirements.

Industry Development/News

Company Name	Date	Key Development
GE Healthcare	Oct-22	GE Healthcare introduced the Omni Legend, an all-digital PET-CT system engineered to deliver higher sensitivity, reduced procedural times, and improved operational efficiency, strengthening the company's competitive positioning within the nuclear imaging devices sector.
Siemens Healthineers AG	Jun-22	Siemens Healthineers received Food and Drug Administration clearance for Symbia Pro.specta, an all-purpose SPECT/CT system integrating advanced computed tomography and single-photon emission computed tomography technologies to expand operational capabilities and market growth opportunities.